MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2025.04.016

Медицинская библиотека · Transplantation and cellular therapy · 2025

Recent Advances in the Prognosis of HHV-6 Encephalitis Following Allogeneic Hematopoietic Stem Cell Transplantation.

Kurihara Kazuya, Sadato Daichi, Toya Takashi, Hirama Chizuko, Kato Kana, Kondo Kaori, Sadaga Yasutaka, Kato Chika, Shimabukuro Masashi, Jinguji Atsushi, Ouchi Fumihiko, Shimizu Hiroaki, Najima Yuho, Harada Yuka, Doki Noriko

СтатьяПеревод в очереди

Аннотация

Human herpesvirus-6 (HHV-6) encephalitis is a rare but fatal complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite advancements in transplantation outcomes and supportive care, knowledge regarding the clinical features and prognostic factors of HHV-6 encephalitis remains limited. This study aims to clarify the clinical characteristics of HHV-6 encephalitis in allo-HSCT recipients and to identify prognostic factors. This is a single-center retrospective study that analyzed the patients with HHV-6 encephalitis who underwent allo-HSCT at our institute between 2004 and 2023. The diagnosis of HHV-6 encephalitis was confirmed by the presence of neurological symptoms and the detection of HHV-6 DNA in the cerebrospinal fluid using real-time polymerase chain reaction. Fifty-three patients were included in this study. The median time from allo-HSCT to HHV-6 encephalitis onset was 24 days (range: 3 to 189). Of the 53 patients, 38 (71.7%) received systemic steroids, with a median interval of 11 days (range: 2 to 46) from steroid initiation to encephalitis onset. One-year overall survival and non-relapse mortality (NRM) after encephalitis diagnosis were 33.5% and 46.5%, respectively. While HHV-6 encephalitis directly caused one death, infections unrelated to HHV-6 were the leading cause of mortality (47.5%). The interval from the onset to the initiation of antiviral therapy was significantly shorter in recent cases (0.0 after 2018 versus 1.5 days before 2017: P = .0086), and 1-year NRM was significantly lower (26.8 versus 62.1%; P = .024). Multivariate analysis revealed that allo-HSCT before 2017 (hazard ratio [HR] 3.13, P = .012) and haploidentical transplantation (HR 3.07, P = .001) were independent prognostic factors for NRM. Among the 32 patients who survived for over 100 days after the initiation of HHV-6 encephalitis treatment, neurological sequelae persisted in 16 (50.0%) cases, including short-term memory impairment in 11. Overall, our study indicates that recent improvements in HHV-6 encephalitis outcomes after allo-HSCT likely result from earlier initiation of antiviral treatment.

Для цитирования: Kurihara Kazuya, Sadato Daichi, Toya Takashi, Hirama Chizuko, Kato Kana, Kondo Kaori, Sadaga Yasutaka, Kato Chika, Shimabukuro Masashi, Jinguji Atsushi, Ouchi Fumihiko, Shimizu Hiroaki, Najima Yuho, Harada Yuka, Doki Noriko. Recent Advances in the Prognosis of HHV-6 Encephalitis Following Allogeneic Hematopoietic Stem Cell Transplantation.. Transplantation and cellular therapy. 2025. DOI: 10.1016/j.jtct.2025.04.016.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.